Welcome to another episode of Real Time Real Talk! Host Cher Pastore speaks to guest, David Tulle who has worked for Dexcom for over 11 years, leading teams across the central Plains, in the mid south and US regions and is currently leading Dexcom’s hospital discharge program. David’s focus is a new approach: integrating Continuous Glucose Monitoring (CGM) systems, such as Dexcom's, into hospital discharge plans for better diabetes management. The conversation covers how the adoption of CGM systems, which provide real-time glucose data, is transforming transitional care strategies from hospital to home, and significantly improving patient outcomes. The second half of the discussion explores Dexcom's innovative initiative to incorporate CGM into hospital discharge plans, streamlining the transition from acute care to home management for patients diagnosed with diabetes. David and Cher discuss how this program provides education and critical tools to newly diagnosed diabetes patients, potentially reducing readmission rates, and offering insight into how Dexcom's initiative could address the need for better disease management strategies post-discharge. They also cover the technology and how it offers real-time insight into glucose levels, aiding patients in their decision making regarding diet, exercise, and medication. The episode also investigates how this strategic introduction into hospital discharge plans can ensure a seamless transition for patients back home, and play a vital role in the prevention of complications and fostering positive patient outcomes. Finally, Cher and David also discuss the collaborative benefits of this program, including how the integration of CGM into discharge planning can empower healthcare professionals to provide better care continuity. They look at why vulnerability in the healthcare system calls for the use of technologies like CGM and how Dexcom's strategy paves the way for a more holistic and technology-driven approach to diabetes management. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide: https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. For more information on the Dexcom Hospital Discharge program visit dexcomprovider.com David Tulle is an employee of Dexcom. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.